Tag:
asthma
Latest Headlines
Latest Headlines
Docs riled by FDA's proposal to open up drug access
The FDA would free up some treatments for chronic conditions, such as asthma and diabetes, so patients could obtain them without a prescription.
Aptar launches new inhaler with eye on emerging markets
Just in time for World Asthma Day, Aptar Pharma is launching a capsule-based dry powder inhaler.
SkyePharma's inhaler takes step toward EMA approval
After years of delays and rejections, SkyePharma is finally getting some good news on Flutiform.
Asthma vaccine hopes rise in preclinical trials
Researchers are developing a DNA-based vaccine targeting Derf1 from the dust mite Dermatophagoides farina.
Targacept scuttles diabetes drug program in fresh setback
A beleaguered Targacept took one step forward and two steps back today, killing a development program for TC-6987.
New year brings new delay for SkyePharma's Flutiform asthma inhaler
It's likely that SkyePharma isn't having a "Happy New Year" just yet. That's because the British drug delivery company now stands to face an additional delay of between 6 and 9 months in the approval
Johns Hopkins tapping genomes to find out why so many African-Americans get asthma
No one is sure why as many as 20% of African-Americans have asthma. Kathleen Barnes will lead an effort to solve the medical mystery. Barnes is an immunogeneticist at The Johns Hopkins University 's
Breaking: Sunovion axes sales reps for asthma meds in consolidation move
Sunovion Pharmaceuticals broke some bad news to sales reps for its respiratory meds this holiday season. The company is consolidating its national respiratory sales organization, laying off a number
Mylan to acquire Pfizer respiratory tech for $17.5M
Mylan ($MYL) will pay $17.5 million to acquire global development, manufacturing and commercialization rights to Pfizer's dry powder respiratory drug delivery system. Pending regulatory...
SkyePharma hit with European delay on Flutiform app
SkyePharma's troubles persisted with its combo asthma product Flutiform, with European regulators unable to meet the drug-delivery specialist's approval timeline. Investors reacted to the news and
